Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR α pathway
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary: Lipotoxicity cardiomyopathy is the result of excessive accumulation and oxidation of toxic lipids in the heart. It is a major threat to patients with diabetes. Glucagon‐like peptide‐1 (GLP‐1) has aroused considerable interest as a novel therapeutic target for diabetes mellitus because it stimulates insulin secretion. Here, we investigated the effects and mechanisms of the GLP‐1 analog exendin‐4 and the dipeptidyl peptidase‐4 inhibitor saxagliptin on cardiac lipid metabolism in diabetic mice (DM). The increased myocardial lipid accumulation, oxidative stress, apoptosis, and cardiac remodeling and dysfunction induced in DM by low streptozotocin doses and high‐fat diets were significantly reversed by exendin‐4 and saxagliptin treatments for 8 weeks. We found that exendin‐4 inhibited abnormal activation of the (PPAR α)‐CD 36 pathway by stimulating protein kinase A (PKA) but suppressing the Rho‐associated protein kinase (ROCK) pathway in DM hearts, palmitic acid (PA)‐treated rat h9c2 cardiomyocytes (CM s), and isolated adult mouse CMs. Cardioprotection in DM mediated by exendin‐4 was abolished by combination therapy with the PPAR α agonist wy‐14643 but mimicked by PPAR α gene deficiency. Therefore, the PPAR α pathway accounted for the effects of exendin‐4. This conclusion was confirmed in cardiac‐restricted overexpression of PPAR α mediated by adeno‐associated virus serotype‐9 containing a cardiac troponin T promoter. Our results provide the first direct evidence that GLP‐1 protects cardiac function by inhibiting the ROCK/PPAR α pathway, thereby ameliorating lipotoxicity in diabetic cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive oxygen species have a causal role in multiple forms of insulin resistance
Houstis, N., Rosen, E. D., & Lander, E. S. (2006) · Nature · doi:10.1038/nature04634 · Cited by 2,525 · cited 1×
“Increased ROS production and reduced antioxidant levels in diabetes have been widely documented in previous reports (Fiordaliso et al., 2004; Houstis et al., 2006).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 9×
“GLP-1R agonists and DPP-4 inhibitors have beneficial effects on the cardiovascular system (Ban et al., 2008; Noyan-Ashraf et al., 2009; Timmers et al., 2009).”
BackgroundInfluentialβ-Cell Glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.
Robertson, R. P., Harmon, J., Tran, P. O. T., & Poitout, V. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s119 · Cited by 914
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“GLP-1R agonists and DPP-4 inhibitors have beneficial effects on the cardiovascular system (Ban et al., 2008; Noyan-Ashraf et al., 2009; Timmers et al., 2009).”
BackgroundBoudina, S., Sena, S., O’Neill, B. T., Tathireddy, P., Young, M. E., & Abel, E. D. (2005) · Circulation · doi:10.1161/circulationaha.105.554360 · Cited by 502 · cited 1×
“ROS damage DNA, mitochondria, and other cellular components by oxidizing proteins, converting lipids into reactive lipid peroxides, and increasing protein tyrosine nitration (Boudina et al., 2005).”
BackgroundFinck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., Gross, R. W., & Kelly, D. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336724100 · Cited by 501
Regulation of energy substrate metabolism in the diabetic heart
Stanley, W. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00047-3 · Cited by 480
Anderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. D. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.031 · Cited by 440
Fitzgibbons, T. P., & Czech, M. P. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000582 · Cited by 331 · cited 1×
“Excessive epicardial fat accumulation closely linked to cardiometabolic disruptions and mortality in T2DM patients through secretion of lipids, adipokines, and pro inflammatory and oxidative factors (Fitzgibbons & Czech, 2014; Gonzalez, Moreno-Villegas, Gonzalez-Bris, Egido & Lorenzo, 2017).”
Background
Cited by
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
The role of CD36 in cardiovascular disease
Shu, H., Peng, Y., Hang, W., Nie, J., Zhou, N., & Wang, D. W. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvaa319 · Cited by 277
Self-citationBizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Metadata
- Authors
- Wu, L., Wang, K., Wang, W., Wen, Z., Wang, P., Liu, L., & Wang, D. W.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2018-04-16
- Volume
- 17
- Issue
- 4
- Pages
- e12763-e12763
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2799989154
- Cited by
- 92
- References
- 17
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR α pathway. https://app.cochat.ai/papers/10.1111/acel.12763
- The paper
- Wu, L., Wang, K., Wang, W., Wen, Z., Wang, P., Liu, L., & Wang, D. W. (2018). Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR α pathway. Aging Cell. https://doi.org/10.1111/acel.12763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.